{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:48:24Z","timestamp":1790354904624,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102893","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:31:40Z","timestamp":1696620700000},"page":"102893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3459-923X","authenticated-orcid":false,"given":"Ernesto","family":"Sosa-Eroza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-7262","authenticated-orcid":false,"given":"Etual","family":"Espinosa-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102893_bib0001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocri Pathol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0002","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the Patient With Prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.arcmed.2023.102893_bib0004","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2023.102893_bib0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0007","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102893_bib0008","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.arcmed.2023.102893_bib0009","first-page":"110","article-title":"Current diagnosis and treatment of hyperprolactinemia","volume":"54","author":"Melgar","year":"2016","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"10.1016\/j.arcmed.2023.102893_bib0010","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-21-0977","article-title":"Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors","volume":"186","author":"Cozzi","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0011","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas?","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102893_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","article-title":"Giant prolactinomas: clinical management and long-term follow up","volume":"97","author":"Shrivastava","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102893_bib0013","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0014","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102893_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12020-017-1469-0","article-title":"Dopamine agonist withdrawal in hyperprolactinemia: when and how","volume":"59","author":"Salvatori","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102893_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-020-02388-0","article-title":"High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?","volume":"70","author":"Espinosa-C\u00e1rdenas","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102893_bib0017","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clini Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"key":"10.1016\/j.arcmed.2023.102893_bib0019","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0020","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jocn.2015.03.059","article-title":"Update on prolactinomas. Part 2: treatment and management strategies","volume":"22","author":"Wong","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.arcmed.2023.102893_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-005-1111-8","article-title":"Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists","volume":"111","author":"Kontogeorgos","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0022","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3389\/fendo.2018.00768","article-title":"The mechanism and pathways of dopamine and dopamine agonists in prolactinomas","volume":"9","author":"Liu","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0023","doi-asserted-by":"crossref","first-page":"39329","DOI":"10.18632\/oncotarget.5744","article-title":"Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2023.102893_bib0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0967-5868(99)90057-7","article-title":"Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression","volume":"6","author":"Yin","year":"1999","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.arcmed.2023.102893_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11102-023-01305-8","article-title":"Refractory lactotroph adenomas","volume":"26","author":"Urwyler","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102893_bib0026","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","article-title":"Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102893_bib0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102893_bib0031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0032","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cen.14714","article-title":"Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and meta-analysis","volume":"97","author":"Andersen","year":"2022","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.arcmed.2023.102893_bib0033","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102893_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2015.00011","article-title":"Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?","volume":"6","author":"Vilar","year":"2015","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102893_bib0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","article-title":"Second attempt to withdraw cabergoline in prolactinomas: a pilot study","volume":"17","author":"Kwancharoen","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102893_bib0036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","article-title":"Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?","volume":"19","author":"Dogansen","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102893_bib0037","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.arcmed.2023.102893_bib0038","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","article-title":"Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas","volume":"10","author":"Indirli","year":"2019","journal-title":"Horm Cancer"},{"key":"10.1016\/j.arcmed.2023.102893_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/167132","article-title":"Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance","volume":"2012","author":"Shimatsu","year":"2012","journal-title":"Clin Dev Immunol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:14:16Z","timestamp":1741184056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001315"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102893","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102893"}}